

FDA approves new pill to reduce pain from endometriosis

July 24 2018, by Linda A. Johnson



This undated image provided by AbbVie in July 2018 shows packaging for the company's drug Orilissa (elagolix). On Tuesday, July 24, 2018, the company said that The Food and Drug Administration approved its the drug for pain during menstruation and at other times. (AbbVie via AP)

A new treatment for pain caused by endometriosis was approved Tuesday by U.S. regulators.

The common condition involves abnormal tissue growth from the uterus that can cause [severe pain](#) and infertility.

Drugmaker Abbvie said the Food and Drug Administration approved the drug, Orilissa, for pain during menstruation and intercourse and at other times. Abbvie says it's the first new pill for endometriosis in a decade.

In testing, it significantly reduced [menstrual pain](#) in about 45 percent of women given a low dose and 75 percent given a high dose, compared to about 20 percent of women given dummy pills. Reduction of pain outside menstruation was slightly lower.

The drug works by reducing production of the [hormone estrogen](#). That caused side effects in some participants, including hot flashes, headaches and bone thinning.

Orilissa will cost \$845 every four weeks, without insurance.

An estimated 1 in 10 women of reproductive age has endometriosis. Treatment usually begins with over-the-counter pain relievers, opioid painkillers and [birth control pills](#). Other options include injections of hormone-suppressing drugs, which have significant side effects, and surgery.

The new pill provides more flexible dosing in lowering estrogen levels, according to Dr. Hugh Taylor of Yale-New Haven Hospital. A consultant to AbbVie, he helped lead key studies of Orilissa.

© 2018 The Associated Press. All rights reserved.

Citation: FDA approves new pill to reduce pain from endometriosis (2018, July 24) retrieved 26 April 2024 from <https://medicalxpress.com/news/2018-07-fda-pill-pain-endometriosis.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.